A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation

Clinical trial NCT00266552 · COMPLETED

Trial details

NCT number: NCT00266552
Sponsor: Janssen Pharmaceutica N.V., Belgium
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Conduct Disorder Disruptive Behavior Disorder Oppositional Defiant Disorder

Enrollment: 118

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.